북미의 유전자 검사 서비스 시장 예측(-2030년) - 지역별 분석 : 서비스 유형별, 질환별, 서비스 프로바이더별

The North America genetic testing services market was valued at US$ 1,604.32 million in 2022 and is expected to reach US$ 4,984.25 million by 2030; it is estimated to register a CAGR of 15.2% from 2022 to 2030.

Growing Preference for Direct-To-Consumer (DTC) Genetic Testing Fuels North America Genetic Testing Services Market

Personalized genetic testing and treatment have long been used globally to help individuals and families learn more about hereditary diseases. Most of the time, genetic testing is done through healthcare personnel, such as genetic counselors. Healthcare providers decide which test is needed, order the test from a test center, collect and send the DNA sample, read the test results, and share the results with the patient. Thus, these tests have traditionally been ordered and interpreted in a clinical or medical research setting. In contrast, DTC genetic testing has witnessed tremendous growth in the past decade and is becoming increasingly widespread.

A genetic test offered, advertised, and sold by companies directly to the consumer, without the direct involvement of a conventional healthcare system, is called DTC genetic testing. DTC genetic testing is relatively new and helps people find out about the disease-associated genes they may carry without the need for a prescription or guidance from a genetic counselor or medical practitioner. Several consumers of DTC testing view it as another method of gathering medical information about themselves.

Unlike other genetic tests performed in clinics or hospitals, the consumer independently initiates and completes a DTC genetic test. The public understanding and acceptance of genetic testing is gradually increasing. Additionally, there is a rise in consumers seeking customized products and experiences for the identification and addressing of unique needs. The launch of innovative products and the increase in the adoption of DTC genetic testing kits have made genetic testing more accessible to people. These kits enable users to undergo personalized health management within the comfort of their homes.

Key industry players are also developing DTC genetic tests and implementing special marketing efforts that positively impact sales of DTC tests. In April 2017, the US Food and Drug Administration (FDA) gave genetics company 23andMe the consent to market DNA tests evaluating the user's level of risk for ten health conditions, including late-onset Alzheimer's disease and Parkinson's disease. These remain the only FDA-approved DTC tests for genetic risk of infection. In July 2023, Quest Diagnostics, a US-based diagnostic information service provider, introduced its first direct-consumer genetic test, Genetic Insights. The test uses next-generation sequencing to evaluate the risk for inheritable health conditions. The test inspects 36 genes using a saliva sample. It can investigate the potential risk of up to 24 genetically inheritable conditions, including breast cancer, heart disorders, blood disorders, and sickle cell anemia.

A rising number of manufacturers are providing direct-to-consumer genetic testing that covers various health conditions and traits. The increasing demand for direct-to-consumer genetic testing products to learn about the genetic makeup and assess the risk of developing hereditary conditions for early disease detection or prevention drives the market.

North America Genetic Testing Services Market Overview

The North America genetic testing services market in North America is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during 2022-2030. The North America genetic testing services market in North America is expected to grow due to the rising number of cancer patients, increasing government funding, and rising incidence of genetic diseases among the population in the US and Canada during recent years. Moreover, increasing focus on advanced method incorporation in healthcare, government and private initiatives for the promotion of precision medicine, and massive funds from government and private bodies for genetic research contribute to exceptional revenue generation for the North America genetic testing services market in North America.

North America Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Million)

North America Genetic Testing Services Market Segmentation

The North America genetic testing services market is categorized into service type, disease, service provider, and country.

Based on service type, the North America genetic testing services market is segmented predictive testing, carrier testing, prenatal testing, newborn screening, and others. The predictive testing segment held the largest market share in 2022.

In terms of disease, the North America genetic testing services market is categorized into cancer, metabolic diseases, cardiovascular diseases, and other diseases. The cancer segment held the largest market share in 2022.

By service provider, the North America genetic testing services market is segmented into hospital-based laboratories, diagnostic laboratories, and others. The hospital-based laboratories segment held the largest market share in 2022.

By country, the North America genetic testing services market is segmented into the US, Canada, and Mexico. The US dominated the North America genetic testing services market share in 2022.

23andMe Holding Co, Ambry Genetics Corp, Eurofins Scientific SE, Exact Sciences Corp, F. Hoffmann-La Roche Ltd, Illumina Inc, Laboratory Corp of America Holdings, NeoGenomics Inc, Centogene AG, and Quest Diagnostics Inc are among the leading companies operating in the North America genetic testing services market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. North America Genetic Testing Services Market - Key Industry Dynamics

• 4.1 Key Market Drivers
  • 4.1.1 Rising Prevalence of Genetic Diseases
  • 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines
  • 4.1.3 Growing Preference for Direct-To-Consumer (DTC) Genetic Testing
• 4.2 Market Restraints
  • 4.2.1 Social and Ethical Implications of Genetic Testing
  • 4.2.2 Affordability of Genetic Services
• 4.3 Market Opportunities
  • 4.3.1 Untapped Emerging Markets in Developing Countries
• 4.4 Future Trends
  • 4.4.1 Artificial Intelligence-Powered Genetic Testing
• 4.5 Impact Analysis:

5. Genetic Testing Services Market - North America Market Analysis

• 5.1 North America Genetic Testing Services Market Revenue (US$ Mn), 2022 - 2030

6. North America Genetic Testing Services Market - Revenue and Forecast to 2030 - by Service Type

• 6.1 Overview
• 6.2 North America Genetic Testing Services Market Revenue Share, by Service Type, 2022 & 2030 (%)
• 6.3 Predictive Testing
  • 6.3.1 Overview
  • 6.3.2 Predictive Testing: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 6.4 Carrier Testing
  • 6.4.1 Overview
  • 6.4.2 Carrier Testing: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 6.5 Prenatal Testing
  • 6.5.1 Overview
  • 6.5.2 Prenatal Testing: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 6.6 Newborn Screening
  • 6.6.1 Overview
  • 6.6.2 Newborn Screening: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 6.7 Others
  • 6.7.1 Overview
  • 6.7.2 Others: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Genetic Testing Services Market - Revenue and Forecast to 2030 - by Disease

• 7.1 Overview
• 7.2 North America Genetic Testing Services Market Revenue Share, by Disease, 2022 & 2030 (%)
• 7.3 Cancer
  • 7.3.1 Overview
  • 7.3.2 Cancer: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Cardiovascular Diseases
  • 7.4.1 Overview
  • 7.4.2 Cardiovascular Diseases: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Metabolic Diseases
  • 7.5.1 Overview
  • 7.5.2 Metabolic Diseases: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 7.6 Other Diseases
  • 7.6.1 Overview
  • 7.6.2 Other Diseases: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Genetic Testing Services Market - Revenue and Forecast to 2030 - by Service Provider

• 8.1 Overview
• 8.2 North America Genetic Testing Services Market Revenue Share, by Service Provider, 2022 & 2030 (%)
• 8.3 Hospital-Based Laboratories
  • 8.3.1 Overview
  • 8.3.2 Hospital-Based Laboratories: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Diagnostic Laboratories
  • 8.4.1 Overview
  • 8.4.2 Diagnostic Laboratories: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Others
  • 8.5.1 Overview
  • 8.5.2 Others: North America Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Genetic Testing Services Market - Country Analysis

• 9.1 North America
  • 9.1.1 North America Genetic Testing Services Market, by Country
    • 9.1.1.1 US
      • 9.1.1.1.1 Overview
      • 9.1.1.1.2 US: North America Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.1.3 US: North America Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
      • 9.1.1.1.4 US: North America Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
      • 9.1.1.1.5 US: North America Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
    • 9.1.1.2 Canada
      • 9.1.1.2.1 Overview
      • 9.1.1.2.2 Canada: North America Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.2.3 Canada: North America Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
      • 9.1.1.2.4 Canada: North America Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
      • 9.1.1.2.5 Canada: North America Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
    • 9.1.1.3 Mexico
      • 9.1.1.3.1 Overview
      • 9.1.1.3.2 Mexico: North America Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.3.3 Mexico: North America Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
      • 9.1.1.3.4 Mexico: North America Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
      • 9.1.1.3.5 Mexico: North America Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)

10. Genetic Testing Services Market-Industry Landscape

• 10.1 Overview
• 10.2 Growth Strategies in Genetic Testing Services Market
• 10.3 Organic Growth Strategies
  • 10.3.1 Overview
• 10.4 Inorganic Growth Strategies
  • 10.4.1 Overview

11. Company Profiles

• 11.1 Eurofins Scientific SE
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 Exact Sciences Corp
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 Laboratory Corp of America Holdings
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 23andMe Holding Co
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 Ambry Genetics Corp
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 Quest Diagnostics Inc
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Services
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 Illumina Inc
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments
• 11.8 F. Hoffmann-La Roche Ltd
  • 11.8.1 Key Facts
  • 11.8.2 Business Description
  • 11.8.3 Products and Services
  • 11.8.4 Financial Overview
  • 11.8.5 SWOT Analysis
  • 11.8.6 Key Developments
• 11.9 NeoGenomics Inc
  • 11.9.1 Key Facts
  • 11.9.2 Business Description
  • 11.9.3 Products and Services
  • 11.9.4 Financial Overview
  • 11.9.5 SWOT Analysis
  • 11.9.6 Key Developments
• 11.10 Centogene AG
  • 11.10.1 Key Facts
  • 11.10.2 Business Description
  • 11.10.3 Products and Services
  • 11.10.4 Financial Overview
  • 11.10.5 SWOT Analysis
  • 11.10.6 Key Developments

12. Appendix

• 12.1 About Us
• 12.2 Glossary of Terms